pCPA
pCPA Brand Process Guidelines Webinar On Friday, June 22nd, 2018 the pan-Canadian Pharmaceutical Alliance Office (pCPAO) hosted an industry consultation session via webinar, on the newly completed pCPA Brand Process Guidelines (“the Guidelines”). The objective of this webinar was to: introduce the Guidelines and supportive documents developed by the pCPA; and invite industry’s initial feedback. This edition of MORSE Signals provides an overview of the webinar and outlines key…
pan-Canadian Pharmaceutical Alliance (pCPA): Negotiation Status Update The May 31, 2018 update has been issued by the pan-Canadian Pharmaceutical Alliance. The key highlights since the last update are: Three negotiations were completed, while three more were closed for a total of 215 completed/closed negotiations; Three new drug products have initiated pCPA negotiations, for a total of 42 active negotiations; One new drug product was added to the “No pCPA…
pan-Canadian Pharmaceutical Alliance (pCPA): Negotiation Status Update The April 30, 2018 update has been issued by the pan-Canadian Pharmaceutical Alliance. The key highlights since the last update are: Seven new drug products have initiated pCPA negotiations, for a total of 46 active negotiations; One negotiation was completed (none closed), for a total of 208 joint completed/closed negotiations; and No new drug products were added to the “No pCPA Negotiations”…
pan-Canadian Pharmaceutical Alliance (pCPA): Negotiation Status Update The March 31, 2018 update has been issued by the pan-Canadian Pharmaceutical Alliance Office (pCPAO). The key highlights since the last update are: Four new drug products have initiated pCPA negotiations, for a total of 40 active negotiations; Two negotiations have been completed (none closed), for a total of 207 joint completed/closed negotiations; and One new drug product was added to the…
MORSE Consulting’s Managing Principal, Sherry O’Quinn, and Principal Consultant, Brad Alyward, are proud to participate in this year’s CADTH Symposium taking place from April 15-17, 2018 in Halifax, Nova Scotia. Further details on MORSE, and its strategic partner’s (Cornerstone Research Group) participation can be found below. April 16, 2018 15:15-16:30 ADT Sherry O’Quinn moderates a panel on oncology drugs with Alex Chambers (CADTH), Scott Gavura (CCO), Elena Lungu…
pan-Canadian Pharmaceutical Alliance (pCPA): Negotiation Status Update The February 28, 2018 update has been issued by the pan-Canadian Pharmaceutical Alliance Office (pCPAO). The key highlights since the last update are: Seven new drug products have initiated pCPA negotiations, for a total of 39 active negotiations; Five negotiations have been completed/closed, for a total of 205 joint completed/closed negotiations; and No new drug products were added to the “No pCPA…
pCPA Monthly Trends & Insights – January 2018 The January 31, 2018 update has been issued by the pan-Canadian Pharmaceutical Alliance Office (pCPAO). The key highlights since the last update are: Two new drug products have initiated pCPA negotiations, for a total of 36 active negotiations; Four negotiations have been completed/closed, for a total of 200 joint completed/closed negotiations; and No new drug products were added to the “No…
Toronto, February 7, 2018: Cornerstone Research Group and MORSE Consulting are pleased to announce the creation of a strategic partnership between our two organizations. This strategic partnership will simplify the logistical process for our clients utilizing our combined services when shepherding a product from reimbursement strategy, to CADTH submission and finally to pCPA negotiations. Together the collaboration between Cornerstone and MORSE offers clients a breadth of reimbursement consulting services…
MORSE Consulting has prepared a Year in Review infographic to highlight some key metrics surrounding the pCPA’s activities in 2017. This analysis highlights completed negotiations broken down in a number of different ways as well as several initiation and negotiation timing measures. MORSE concludes the analysis with our overall perspective on pCPA’s activities over the past year. Click here to view full-size infographic Click here to view full-size…
pan-Canadian Pharmaceutical Alliance (pCPA): Negotiation Status Update The December 31, 2017 update has been issued by the pan-Canadian Pharmaceutical Alliance Office (pCPAO). The key highlights from the pCPAO since the last update are: Five new drug products have initiated pCPA negotiations, for a total of 36 active negotiations; Eight negotiations have been completed/closed, for a total of 196 joint completed/closed negotiations; and One new drug product was added to…
pan-Canadian Pharmaceutical Alliance (pCPA): Negotiation Status Update The November 30, 2017 update has been issued by the pan-Canadian Pharmaceutical Alliance Office (pCPAO). The key highlights from the pCPAO since the last update are: Four new drug products have initiated pCPA negotiations, for a total of 39 active negotiations; Eleven negotiations have been completed/closed, for a total of 188 joint completed/closed negotiations; and One new drug product was added to…
pan-Canadian Pharmaceutical Alliance (pCPA): Negotiation Status Update The October 31, 2017 update has been issued by the pan-Canadian Pharmaceutical Alliance Office (pCPAO). The key highlights from the pCPAO since the last update are: Two new drug products have initiated pCPA negotiations, for a total of 46 active negotiations; Seven negotiations have been completed/closed, for a total of 177 joint completed/closed negotiations; and No new drug products were added to…
pan-Canadian Pharmaceutical Alliance (pCPA): Negotiation Status Update The September 30, 2017 update has been issued by the pan-Canadian Pharmaceutical Alliance Office (pCPAO). The key highlights from the pCPAO since the last update are: Six new drug products have initiated pCPA negotiations, for a total of 51 active negotiations; Two negotiations have been completed/closed, for a total of 170 joint completed/closed negotiations; and One new drug product was added to…
Mani & O’Quinn Reimbursement Strategy Experts (MORSE) Consulting Inc. is pleased to introduce MORSE LINKS, a new feature on our website. MORSE LINKS provides a comprehensive list of useful web links which can allow market access professionals to easily access frequently referenced web sites. Similar to other services offered by MORSE, LINKS has a user-friendly interface with information separated into broad categories to allow users to sort and search based…
pan-Canadian Pharmaceutical Alliance (pCPA): Negotiation Status Update The August 31, 2017 update has been issued by the pan-Canadian Pharmaceutical Alliance Office (pCPAO). The key highlights from the pCPAO since the last update are: Six new drug products have initiated pCPA negotiations, for a total of 47 active negotiations; Five negotiations have been completed, for a total of 168 joint negotiations; and One new drug product was added to the…
Contact Us
MORSE Consulting Inc.
MORSE Consulting Inc. | Deciphering Canadian pharmaceutical market access signals to create reimbursement success.
© 2023 MORSE Consulting Inc. All rights reserved. |
Site by Directica Media
pCPA - Info and details on - Page 7 of 9 - MORSE Consulting Inc.
